Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate (vol 16, pg 888, 2010)

被引：1
|
作者：
Okeley, N. M.
Miyamoto, J. B.
Zhang, X.
Sanderson, R. J.
Benjamin, D. R.
Sievers, E. L.
机构：
来源：
CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 16期
关键词：
D O I：
10.1158/1078-0432.CCR-11-1753
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5524 / 5524
页数：1
相关论文
共 50 条
  • [1] Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
    Okeley, Nicole M.
    Miyamoto, Jamie B.
    Zhang, Xinqun
    Sanderson, Russell J.
    Benjamin, Dennis R.
    Sievers, Eric L.
    Senter, Peter D.
    Alley, Stephen C.
    CLINICAL CANCER RESEARCH, 2010, 16 (03) : 888 - 897
  • [2] The anti-CD30 antibody-drug conjugate SGN-35 is a potent therapy for the treatment of CD30+malignancies
    Barton, J
    Hamblett, K
    Cerveny, C
    Andreyka, J
    Kissler, K
    Stone, I
    Sun, M
    Senter, P
    Wahl, A
    Francisco, J
    Ihle, N
    ANNALS OF ONCOLOGY, 2005, 16 : 134 - 134
  • [3] SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies.
    Hamblett, KJ
    Barton, J
    Cerveny, CG
    Andreyka, JB
    Kissler, KM
    Okeley, NM
    Stone, I
    Sutherland, MK
    Sun, MM
    Senter, PD
    Wahl, AF
    Ihle, NC
    BLOOD, 2005, 106 (11) : 181A - 181A
  • [4] Specific tumor targeting and potent bystander killing with SGN-35, an anti-CD30 antibody drug conjugate.
    Okeley, Nicole M.
    Alley, Stephen C.
    Cerveny, Charles G.
    Andreyka, Jamie
    Sanderson, Russell J.
    Anderson, Martha
    Benjamin, Dennis R.
    Law, Che-Leung
    Sievers, Eric
    Ihle, Nathan C.
    BLOOD, 2006, 108 (11) : 72A - 72A
  • [5] Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies
    Gualberto, Antonio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) : 205 - 216
  • [6] THE PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN (SGN-35), AN ANTIBODY-DRUG CONJUGATE (ADC).
    Han, T. H.
    Kennedy, D.
    Hayes, S.
    Lynch, C. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S51 - S51
  • [7] Brentuximab vedotin: An anti-CD30 antibody-drug conjugate
    Bradley, Amber M.
    Devine, Meghan
    DeRemer, David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (07) : 589 - 597
  • [8] BRENTUXIMAB VEDOTIN Anti-CD30 Antibody-Drug Conjugate Oncolytic
    Copeland, A.
    Younes, A.
    DRUGS OF THE FUTURE, 2010, 35 (10) : 797 - 801
  • [9] Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
    Oflazoglu, Ezogelin
    Kissler, Kim M.
    Sievers, Eric L.
    Grewal, Iqbal S.
    Gerber, Hans-Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (01) : 69 - 73
  • [10] Combination of the anti-CD30-auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin lymphoma
    Gerber, H. P.
    Oflazoglu, E.
    Kissler, K.
    Kennedy, D.
    Sievers, E. L.
    Ihle, N. C.
    Meyer, D. L.
    Grewal, I. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 166 - 166
12345